Profusa (PFSA)
Injectable hydrogel biosensors and optical readers for continuous body-chemistry monitoring.
Something off on this page? Send us feedback.
Develops Lumee injectable hydrogel biosensors, optical readers, and software for tissue oxygen and clinical-stage glucose monitoring. The company is pre-revenue and relies on regulatory authorization, particularly European MDR certification for Lumee Oxygen, before clinical commercialization.
Develops Lumee, which pairs injectable, tissue-integrated hydrogel biosensors with wearable optical readers and mobile software to continuously measure body chemistry. Lumee Oxygen monitors local tissue oxygen, and Lumee Glucose is a clinical-stage continuous-glucose-monitoring candidate. Research-use tissue-oxygen kits and service-enabled offerings are available to contract research organizations, while clinical commercialization has not begun.
Separates a passive injectable sensor from a reusable optical reader; the hydrogel contains no electronics or power source, while reader software turns fluorescence and temperature data into values. Research, management, and most implantable-sensor production are in Berkeley, supported by qualified outside vendors. Europe is Lumee Oxygen's lead clinical-commercial geography, but its commercialization depends on MDR certification; neither Lumee Oxygen nor Lumee Glucose holds U.S. marketing authorization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $719.0K · Total debt $14.0M · Total assets $1.0M · Shareholders' equity −$27.1M
- Revenue
- $0
- Operating income
- −$2.5M
- Net income
- −$8.8M
No dividends on record.
| Institutions | 0.20% | 2.2K shares | |
|---|---|---|---|
| 8 holders · as of Jun 30, 2026 | |||
| Insiders | 7.86% | 86.7K shares | |
| 5 holders · as of Sep 4, 2026 | |||
| Other | 91.94% | 1.01M shares | |
| remainder | |||
1.10M company shares as of Aug 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Fred S. KnechtelInsiderofficer: Chief Financial Officer | 4.94% | 54,470 | filed Sep 4, 2026 |
Jack E. StoverInsiderofficer: Chief Executive Officer | 2.91% | 32,091 | filed Sep 4, 2026 |
HRT Financial LPInstitution | 0.16% | 170,946 | as of Jun 30, 2026 |
Stonex Group Inc.Institution | 0.02% | 16,879 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.01% | 16,417 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | HRT Financial LP | 10 percent owner | −18,395 | $5.94 |
| Aug 14, 2026 | HRT Financial LP | 10 percent owner | −3,163 | $0.9020 |
| Aug 13, 2026 | HRT Financial LP | 10 percent owner | −42,411 | $0.8880 |
| Aug 12, 2026 | HRT Financial LP | 10 percent owner | +5,585 | $0.9640 |
| Aug 11, 2026 | HRT Financial LP | 10 percent owner | −2,280 | $0.9700 |
- Dexcom
Scaled CGM incumbent across personal and professional use.
- Abbott
FreeStyle Libre is a major commercial CGM alternative.
- Senseonics
Long-duration implantable CGM alternative with a one-year sensor.
- Medtronic
Simplera and MiniMed combine CGM with insulin delivery.
- Philips (ADR)
Angiography and CT compete for peripheral-perfusion workflow.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Profusa | $1.94 | −10.80% | $2.1M | — | — | — | — |
| Dexcom | $90.00 | +0.54% | $33.65B | 35.2 | 31.9 | 6.8 | +13.1% |
| Abbott | $103.69 | −0.03% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Senseonics | $10.00 | −0.50% | $408.7M | — | — | 8.4 | +118.1% |
| Medtronic | $90.77 | 0.00% | $117.44B | 22.6 | 15.1 | 3.1 | +13.7% |
| Philips (ADR) | $24.97 | −0.06% | $24.34B | 18.7 | 13.0 | 1.2 | −2.8% |
| Median | 27.9 | 16.5 | 3.8 | +13.1% |